Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director · Chief Operating Officer · 10% owner | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy way of LifeSci Investments, LLC | 1,701,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,701,000 F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rice is a managing member of LifeSci Investments, LLC. He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in LifeSci Investments, LLC.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 30, 2023 · Filed November 01, 2023
Section 16 reporting ended · disclosed 2023-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 347,085 |
Reported balance
After 2023-10-30 transaction · row 1
1 source rowRow 1 · 2023-10-30 · Sale · Disposed 72,603 · Balance 347,085 F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported herein was made pursuant to Rule 10b5-1 (c) trading plans adopted by the reporting person effective as of 03-25-2020, 02-08-21, 02-24-2022, and 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,769 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $52.59 | $602,733.99 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,462 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.24 to $53.22, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,230 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $52.50 | $601,702.50 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,462 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.91 to $53.32, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 07, 2021 Filed Sep 10, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-021860 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2021 Filed Aug 31, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 848 | $57.26 | $48,556.48 |
DisclosureSEC source: 0001437749-21-021219 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,462 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,691 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $48.37 | $554,368.57 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.8 to $48.66, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 05, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,152 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| August 03, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $48.26 | $553,107.86 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.93 to $48.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2021 Filed Aug 6, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-018816 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-018182 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,310 F1 · kind: This transaction represents a charitable donation to a third party. No value was received for the gifted shares. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,464 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,613 Underlying: Common Stock · 11,464 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,464 | $46.15 | $529,063.60 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.15 to $47.93, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,464 | $1.64 | $18,800.96 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,077 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $46.28 | $530,415.08 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,310 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.22 to $46.80, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 06, 2021 Filed Jul 9, 2021 01:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-016690 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 902 | $43.75 | $39,462.50 |
DisclosureSEC source: 0001437749-21-016267 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,310 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,538 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $36.47 | $417,982.67 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,212 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.85 to $36.87, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,999 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| June 08, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $35.54 | $407,323.94 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,212 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $36.33, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 08, 2021 Filed Jun 11, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-014534 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2021 Filed Jun 3, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 802 | $33.87 | $27,163.74 |
DisclosureSEC source: 0001437749-21-014006 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,212 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 06, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,460 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| May 06, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $30.41 | $348,529.01 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 06, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · derivative · entry 5 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,921 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| May 04, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $30.15 | $345,549.15 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.70 to $33.51, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 04, 2021 Filed May 7, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-011203 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,487 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008950 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,014 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months. Read SEC document |
| April 08, 2021 Filed Apr 13, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-008759 · rdgdoc.xml · derivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,382 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
| April 08, 2021 Filed Apr 13, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 11,461 | $35.32 | $404,802.52 |
DisclosureSEC source: 0001437749-21-008759 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,527 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.92 to $35.66, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 08, 2021 Filed Apr 13, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 11,461 | $1.64 | $18,796.04 |
DisclosureSEC source: 0001437749-21-008759 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,149 | $36.53 | $370,742.97 |
DisclosureSEC source: 0001437749-21-008328 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,527 F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 26,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008328 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,809 | $35.01 | $133,353.09 |
DisclosureSEC source: 0001437749-21-007719 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,522 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 861 | $39.57 | $34,069.77 |
DisclosureSEC source: 0001437749-21-004768 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,331 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,107 | $40.76 | $411,961.32 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 5 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,192 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,132 | $40.67 | $412,068.44 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 4 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,299 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 9,917 | $41.55 | $412,051.35 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 3 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,431 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 7,511 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · derivative · entry 6 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,511 Underlying: Common Stock · 7,511 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 70,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 2 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 7,511 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003514 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,354 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 813 | $35.49 | $28,853.37 |
DisclosureSEC source: 0001437749-20-024806 · rdgdoc.xml · nonDerivative · entry 1 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,843 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionEmployee Stock Option · Derivative | 11,461 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-20-024045 · rdgdoc.xml · derivative · entry 9 Rice Michael · CIK 0001389512 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,843 Underlying: Common Stock · 11,461 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in two equal annual installments based on the registrant's satisfaction of certain performance criteria for the fiscal year ending December 2017. The performance criteria for 2017 were met, resulting in vesting of the option as follows: 114,613 shares vested on March 8, 2018 and 114,613 shares vested on March 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.